Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer

NEXT STORY
Novan Receives Phase 2 NIH Federal Grant of Approximately $1.0 Million
PREV STORY
Global Metagenomics Market Report 2020; Forecast to 2027
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Baudax Bio Announces FDA Approval of ANJESO™ for the Management of Moderate to Severe Pain

author_avatar
NASDAQ Market News

Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer

author_avatar
NASDAQ Market News

electroCore Submits Emergency Use Authorization Application to Allow the Study and Use of gammaCore nVNS Therapy to Treat Respiratory Symptoms Associated with COVID-19

author_avatar
NASDAQ Market News